contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


attana-dear-shareholders-and-valuable-followers

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Attana conducts research and development of pharmaceuticals. The company specialises in vitro characterization of molecular interactions, which is used for analysis in the development of new pharmaceuticals. The company's patented solutions are mainly used in the study of different binding properties and macrostructures in cells, proteins, viruses, and bacteria. Operations are found mainly within the Nordic countries and Europe. The company was established in 2002 is based in Stockholm.

Attana

It is with great joy and enthusiasm that I take on the role as CEO of Attana. As mentioned in the first press release, the board aims to bring about a change, increasing sales by reprioritizing...

<div class="abstract">It is with great joy and enthusiasm that I take on the role as CEO of Attana. As mentioned in the first press release, the board aims to bring about a change, increasing sales by reprioritizing the time for the team to focus more on the commercial agenda, and work more structed with customer relations and product development. This is a good starting point and in line with my short-term strategy.</div>Another short-term goal for Attana is to become cash flow positive. To balance revenues and costs is the foundation of all sustainable businesses, and we need to take decisions in line with that strategy. Concurrently, we are restructuring our customer relationships and defining clearer roles and responsibilities internally while reviewing our cost level. Commercially, we are focusing on five revenue streams: CRO, instrument sales, service, consumables, and immunity profiles. The first four are related to our traditional Life Science business and will be the backbone of our business in the coming year. The fifth revenue stream, the immunity profiles, is connected to Diagnostics and defined as our growth market.Shortly, I will participate in a podcast where I will share my views and ideas on how to stabilize and grow our business. We will share the event in our social media channels in mid-October.Our technology and the IP we hold is world-leading but also underestimated by markets and certain conservative competitors and customers. I can understand that, but I can't accept it. We shall work hard to convince the market differently. As a team, we shall be present and assist our customers in their highly important projects, exceed their expectations and solve their scientific problems continuously. More than 150 publications and the outcome from our customers' clinical trials sends a clear message, the drug development process can be improved and yet more cost efficient with our technology. Additionally, increased cost savings for hospitals through more precise diagnostics, and an improved understanding among citizens regarding their own vaccine protection is very beneficial for the society but not yet addressed.Thank you for being an important part of our global community.Best regards,Marcus Söderberg CEO, Attana

Attana: Dear shareholders and valuable followers,

Voittajan kirous

Yhdysvallat velkaantuu ja dollari heikkenee: Onko eurosta turvasatamaksi?

Pörsseissä ongitaan taas uusia huippuja, politikointi päällä Fed-valinnoissa

Pienyhtiöt ovat jääneet isoista jälkeen alkuvuoden nousumarkkinassa

Euroopan talouskasvu murrosvaiheessa: Mikä vielä pidättelee Eurooppaa?